LinkedIn Profile

Access Xellia Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xellia 1181570 Oct 21st, 2019 12:00AM Xellia Pharmaceuticals 26K 1250 Open Pharmaceuticals Oct 21st, 2019 04:00PM Oct 21st, 2019 04:00PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 20th, 2019 12:00AM Xellia Pharmaceuticals 26K 1250 Open Pharmaceuticals Oct 20th, 2019 02:24PM Oct 20th, 2019 02:24PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 19th, 2019 12:00AM Xellia Pharmaceuticals 26K 1249 Open Pharmaceuticals Oct 19th, 2019 01:49PM Oct 19th, 2019 01:49PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 18th, 2019 12:00AM Xellia Pharmaceuticals 26K 1249 Open Pharmaceuticals Oct 18th, 2019 01:29AM Oct 18th, 2019 01:29AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 17th, 2019 12:00AM Xellia Pharmaceuticals 26K 1250 Open Pharmaceuticals Oct 17th, 2019 12:04PM Oct 17th, 2019 12:04PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 16th, 2019 12:00AM Xellia Pharmaceuticals 26K 1249 Open Pharmaceuticals Oct 16th, 2019 01:51AM Oct 16th, 2019 01:51AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 15th, 2019 12:00AM Xellia Pharmaceuticals 26K 1249 Open Pharmaceuticals Oct 15th, 2019 01:39PM Oct 15th, 2019 01:39PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 14th, 2019 12:00AM Xellia Pharmaceuticals 26K 1246 Open Pharmaceuticals Oct 14th, 2019 02:03PM Oct 14th, 2019 02:03PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 13th, 2019 12:00AM Xellia Pharmaceuticals 26K 1249 Open Pharmaceuticals Oct 13th, 2019 10:46AM Oct 13th, 2019 10:46AM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300
private:xellia 1181570 Oct 12th, 2019 12:00AM Xellia Pharmaceuticals 26K 1248 Open Pharmaceuticals Oct 12th, 2019 12:39PM Oct 12th, 2019 12:39PM Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1500 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS). Our success and strong market position is built on more than 100 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Custom Synthesis, Injectables Open Dalslandsgade 11 Copenhagen DK 2300

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.